Keyphrases
Venous Thromboembolism
86%
Splanchnic Vein Thrombosis
61%
Emicizumab
57%
Anticoagulant Treatment
45%
Pediatric
44%
Thrombin Generation
42%
Thrombosis
42%
Hemophilia
40%
Direct Oral Anticoagulants
39%
Meta-analysis
38%
Systematic Meta-analysis
36%
Inherited Thrombophilia
36%
Recurrent Venous Thromboembolism
32%
Confidence Interval
30%
Anticoagulant Therapy
30%
Pediatric Patients
27%
Clinical Outcomes
27%
Cancer-related
25%
Anticoagulation
25%
Enfermedad
24%
Anticoagulants
23%
Bleeding
23%
Hemostasis
22%
Major Bleeding
21%
Bleeding Complications
19%
Factor VIII Inhibitor
17%
Tertiary Care Hospital
17%
Clinical Characteristics
15%
Coagulation Factors
14%
Longitudinal Follow-up
14%
Developmental Hemostasis
14%
FVIII Inhibitors
14%
Hospitalization
14%
Haemophilia Treatment Centre
14%
Bleeding Risk
14%
Clinical Presentation
13%
Recurrence Rate
13%
Factor VIII (FVIII)
12%
Older Adults
12%
Cerebral Venous Thrombosis
12%
Acute Myeloid Leukemia
12%
Pharmacy
12%
Splenic Infarction
12%
Thromboembolism
12%
Bleeding Phenotype
12%
Neutrophil-to-lymphocyte Ratio
12%
GARFIELD
12%
Chemotherapy Treatment
12%
Noonan Syndrome
12%
Leukemia Patients
12%
Medicine and Dentistry
Venous Thromboembolism
65%
Thrombosis
56%
Bleeding
53%
Phlebothrombosis
53%
Anticoagulant Therapy
52%
Pediatrics
51%
Emicizumab
44%
Haemophilia A
42%
Blood Stasis
35%
Malignant Neoplasm
32%
Thrombin
31%
Thrombophilia
28%
Direct Oral Anticoagulant
26%
Meta-Analysis
26%
Systematic Review
24%
Anticoagulation
24%
Hemostat
22%
Anticoagulant
17%
Recurrent Disease
17%
Major Bleeding
16%
Blood Clotting Factor 8 Inhibitor
16%
Factor XI
16%
Thromboembolism
15%
Prospective Study
14%
Blood Clotting Factor
13%
Recanalization
13%
Pediatrics Patient
12%
Inferior Vena Cava
12%
Splenic Infarction
12%
Noonan Syndrome
12%
Acute Myeloid Leukemia
12%
Long Term Survival
12%
Immunological Tolerance
12%
Cerebral Sinus Thrombosis
12%
Acute Pulmonary Embolism
12%
Tissue Factor Pathway Inhibitor
12%
Bleeding Disorder
12%
Ex Vivo
12%
Heparin-Induced Thrombocytopenia
12%
Lymphocyte
12%
Neutrophil
12%
Cancer
11%
Marstacimab
10%
Blood Clotting Factor 8
10%
Invasive Procedure
10%
Patient with Hemophilia
9%
Recurrence Risk
9%
Neonate
8%
Immunosuppressive Treatment
8%
Side Effect
8%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
100%
Anticoagulant Agent
78%
Emicizumab
55%
Haemophilia A
53%
Bleeding
52%
Vein Thrombosis
38%
Thrombophilia
36%
Thrombosis
35%
Direct Oral Anticoagulant
32%
Thrombin
28%
Recurrent Disease
22%
Blood Clotting Factor 8 Inhibitor
16%
Blood Stasis
16%
Thromboembolism
16%
Blood Clotting Factor 11
14%
Diseases
14%
Liver Cirrhosis
12%
Spleen Infarction
12%
Acute Myeloid Leukemia
12%
Rivaroxaban
12%
Cerebral Sinus Thrombosis
12%
Chemotherapy
12%
Long Term Survival
12%
Tissue Factor Pathway Inhibitor
12%
Bleeding Disorder
12%
Coronavirinae
12%
Remission
12%
Recurrence Risk
10%
Marstacimab
10%
Blood Clotting Factor 8
8%
Malignant Neoplasm
7%
Antivitamin K
7%
Blood Clotting Disorder
7%
Lower Extremity Deep Vein Thrombosis
6%
Hemostatic Agent
6%
Autoimmune Disease
6%
Side Effect
6%
Immunosuppressive Agent
6%
Replacement Therapy
5%
All Cause Mortality
5%
Comorbidity
5%
Retrospective Study
5%
Mortality Rate
5%